1774 unknown. 1774 Phase 2, 298 Phase 1, 179 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1774 | Unknown 1774 |
| Phase 1 | 298 | Unknown 298 |
| Phase 3 | 179 | Unknown 179 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2024-10-02 | 2024-10-01 |
| Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis Parecoxib Sodium, Indomethacin suppository - Pancreatitis, Acute, Cholangiopancreatography, Endoscopic Retrograde | Phase 2 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 100 | 2024-10-01 | 2024-10-02 |
| Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab, CAPOX Chemotherapy - Microsatellite Stable (MSS) Colon Cancer, Locally Advanced Colon Cancer | Phase 2 | Unknown | Sir Run Run Shaw Hospital | 140 | 2024-10-01 | 2024-09-19 |
| BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma BTLA inhibitor (JS004), Toripalimab, Paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Henan Provincial People's Hospital | 20 | 2024-09-30 | 2024-09-19 |
| Exploring Treatments for Children's Abdominal Pain: Comparing Trimebutine and Probiotics Trimebutine, Lactobacillus rhamnosus, Placebo - Functional Abdominal Pain Syndrome, Functional Gastrointestinal Disorders | Phase 1 / Phase 2 | Unknown | Universidad de Colima | 82 | 2024-09-01 | 2024-08-16 |
| Beta-Hydroxybutyrate Feasibility Treating IBD Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's - Crohn's Disease, Inflammatory Bowel Diseases | Phase 1 / Phase 2 | Unknown | University of Texas at Austin | 20 | 2024-08-28 | 2024-09-19 |
| A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation Camrelizumab, Apatinib - Hepatocellular Carcinoma | Phase 2 | Unknown | Zhujiang Hospital | 38 | 2024-08-26 | 2024-08-09 |
| Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders MTP-101P, Vancomycin, Miralax - Autism Spectrum Disorder, Gastro-Intestinal Disorder | Phase 2 | Unknown | Gut-Brain-Axis Therapeutics Inc. | 60 | 2024-08-20 | 2024-09-25 |
| Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study FOLFOXIRI Protocol - Neoplasm Malignant, Colon Cancer Stage 4 | Phase 2 | Unknown | Al-Azhar University | 60 | 2024-08-17 | 2024-08-28 |
| Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD TLC-2716 Dose 1, TLC-2716 Dose 2, Placebo - Hypertriglyceridemia, Nonalcoholic Fatty Liver Disease | Phase 2 | Unknown | OrsoBio, Inc | 30 | 2024-08-12 | 2025-04-03 |
| Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer Irinotecan Liposome, Bevacizumab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Unknown | West China Hospital | 20 | 2024-08-09 | 2024-08-09 |
| A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis Sintilimab, Ramucirumab, SOX/XELOX - Stomach Neoplasms | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 39 | 2024-08-01 | 2024-08-28 |
| Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma Cryoablation, PD-1 antibody and bevacizumab - Carcinoma, Hepatocellular | Phase 2 | Unknown | Shanghai Zhongshan Hospital | 36 | 2024-07-31 | 2024-07-31 |
| Prospective Phase II Study on Continuous Circumferential Reinforcement of Laparoscopic Rectal Anastomosis to Prevent Complications Continuous Circumferential Reinforcement of the Anastomotic - Colorectal Cancer, Anastomotic Leakage | Phase 2 | Unknown | ZHI-ZHONG PAN | 208 | 2024-07-20 | 2024-07-11 |
| HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450 - Hepatocellular Carcinoma | Phase 2 | Unknown | Fudan University | 42 | 2024-07-20 | 2024-06-26 |
| MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer PD-1 monoclonal antibody consolidation therapy - Esophageal Cancer | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 102 | 2024-07-16 | 2024-08-06 |
| Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. Adebrelimab, Apatinib, Investigator chosen chemotherapy (ICC) - Esophageal Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Henan University of Science and Technology | 54 | 2024-07-15 | 2024-06-18 |
| Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer Trilaciclib Injection [Cosela], Placebo - Esophageal Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2024-07-09 | 2024-08-26 |
| Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma Autologous Tumor-infiltrating Lymphocytes - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Beijing 302 Hospital | 20 | 2024-07-01 | 2024-08-13 |
| First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer mfolfox6 and hlx04 regimen and Serplulimab, mfolfox6 and hlx04 regimen - Efficacy, Self, Safety Issues | Phase 2 | Unknown | Sir Run Run Shaw Hospital | 72 | 2024-07-01 | 2024-07-09 |
Showing 20 of 1774. Sign in to see all of them.
Colorectal Neoplasms (324) · Stomach Neoplasms (285) · Carcinoma, Hepatocellular (241) · Pancreatic Neoplasms (163) · Rectal Neoplasms (123) · Esophageal Neoplasms (121) · Esophageal Squamous Cell Carcinoma (102) · Colonic Neoplasms (90) · Liver Neoplasms (53) · Neoplasm Metastasis (48) · Biliary Tract Neoplasms (40) · Neoplasms (39) · Liver Cirrhosis (35) · Colitis, Ulcerative (33) · Non-alcoholic Fatty Liver Disease (27)
Neoplasms by Site (1389) · Digestive System Neoplasms (1377) · Neoplasms (1377) · Gastrointestinal Diseases (1103) · Gastrointestinal Neoplasms (922) · Intestinal Diseases (589) · Intestinal Neoplasms (475) · Colonic Diseases (438) · Rectal Diseases (438) · Liver Diseases (437) · Neoplasms by Histologic Type (419) · Neoplasms, Glandular and Epithelial (394) · Carcinoma (373) · Stomach Diseases (301)
Oxaliplatin (159) · Capecitabine (124) · Fluorouracil (111) · Irinotecan (89) · Leucovorin (73) · Cisplatin (70) · S 1 (combination) (70) · apatinib (70) · Paclitaxel (66) · Bevacizumab (64) · sintilimab (63) · Gemcitabine (60) · camrelizumab (57) · Radiotherapy (51) · Drug Therapy (50)
Fudan University (74) · Sun Yat-sen University (73) · Tianjin Medical University Cancer Institute and Hospital (39) · Shanghai Zhongshan Hospital (27) · Chinese Academy of Medical Sciences (26) · Zhejiang Cancer Hospital (24) · Peking University (19) · National Cancer Center, Korea (18) · Chinese PLA General Hospital (17) · National Taiwan University Hospital (17) · Second Affiliated Hospital, Zhejiang University, School of Medicine (17) · The First Affiliated Hospital with Nanjing Medical University (17) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (16) · Samsung Medical Center (16) · Yonsei University (16)
China (825) · United States (145) · South Korea (109) · France (51) · Taiwan (45) · Netherlands (40) · United Kingdom (40) · Italy (39) · Japan (35) · Germany (34) · Spain (32) · Canada (31) · Israel (27) · Brazil (22) · Singapore (20)
Feng Wang (5) · Lin Shen, MD (5) · Lin Shen, Professor (5) · Wei Peng Yong, MRCP, MB ChB (5) · Subrat K Acharya, DM (4) · Cathy Hammerman, MD (3) · Christophe Louvet, MD, PhD (3) · Daiming Fan (3) · Fuxiang Zhou, M.D. (3) · Gang Jin, Doctor (3) · Gao-Jun Teng, MD (3) · Haitao Zhao, MD (3) · Hui-Ju Ch'ang, M.D. (3) · Jian Zhou (3) · Jingdong Zhang (3)
PMID 30642373, PMID 35623069, PMID 12049862, PMID 12540794, PMID 15273542, PMID 20516446, PMID 23547081, PMID 25447852, PMID 25514302, PMID 26313683, PMID 26755520, PMID 26884585, PMID 27480145, PMID 28434648, PMID 30348638, PMID 32306237, PMID 34725214, PMID 35219300, PMID 36657089, PMID 37981041, PMID 38421211, PMID 39863139, PMID 41379261, PMID 9146781, PMID 10089184, PMID 10091726, PMID 10400410, PMID 10615932, PMID 10744089, PMID 11091234, PMID 11223832, PMID 11231246, PMID 11239312, PMID 11247898, PMID 11248153, PMID 11251976, PMID 11289756, PMID 11413430, PMID 11419162, PMID 11491192, PMID 11574279, PMID 11712875, PMID 11754382, PMID 11813623, PMID 11896099, PMID 11914441, PMID 11981766, PMID 12091661, PMID 12187070, PMID 12196368
2016 (6), 2009 (5), 2018 (5), 2019 (5), 2008 (4), 2015 (4), P30CA015083 (4), 2014 (3), 2017 (3), 2005 (2), 2023 (2), K08HD052885 (1), M01RR000096 (1), P20CA252732 (1), P30CA168524 (1)